Title
Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture

Permalink
https://escholarship.org/uc/item/0r0555vk

Journal
Journal of Neurochemistry, 131(4)

ISSN
0022-3042

Authors
Han, Z
Li, L
Wang, L
et al.

Publication Date
2014-11-01

DOI
10.1111/jnc.12817

Peer reviewed
Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture

Zhenying Han,*† Li Li,* Liang Wang,* Vincent Degos,*‡ Mervyn Maze* and Hua Su*

*Department of Anesthesia and Perioperative Care, Center for Cerebrovascular Research, University of California, San Francisco, San Francisco, California, USA
†Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China
‡INSERM, U676, Hôpital Robert Debré, Paris, France

Abstract
Bone fracture at the acute stage of stroke exacerbates stroke injury by increasing neuroinflammation. We hypothesize that activation of α-7 nicotinic acetylcholine receptor (α-7 nAchR) attenuates neuroinflammation and oxidative stress, and reduces brain injury in mice with bone fracture and stroke. Permanent middle cerebral artery occlusion (pMCAO) was performed in C57BL/6J mice followed by tibia fracture 1 day later. Mice were treated with 0.8 mg/kg PHA 568487 (PHA, α-7 nAchR-specific agonist), 6 mg/kg methyllycaconitine (α-7 nAchR antagonist), or saline 1 and 2 days after pMCAO. Behavior was tested 3 days after pMCAO. Neuronal injury, CD68+ M1 (pro-inflammatory) and M2 (anti-inflammatory) microglia/macrophages, phosphorylated p65 component of nuclear factor kappa b in microglia/macrophages, oxidative and anti-oxidant gene expression were quantified. Compared to saline-treated mice, PHA-treated mice performed better in behavioral tests, had fewer apoptotic neurons (NeuN+ TUNEL+), fewer CD68+ and M1 macrophages, and more M2 macrophages. PHA increased anti-oxidant gene expression and decreased oxidative stress and phosphorylation of nuclear factor kappa b p65. Methyllycaconitine had the opposite effects. Our data indicate that α-7 nAchR agonist treatment reduces neuroinflammation and oxidative stress, which are associated with reduced brain injury in mice with ischemic stroke plus tibia fracture.

Keywords: macrophage polarization, middle cerebral artery occlusion, neuroinflammation, oxidative stress.


Stroke is the fourth leading cause of death in the United States (Go et al. 2013) and an important risk factor for bone fracture (Kanis et al. 2001). About 70 000 people experience a fracture within the first year, and in the United States about 1–1.5% of fractures occur within the first 24 h of stroke (Kanis et al. 2001). We have shown that bone fracture 1 day after ischemic stroke in mice exacerbates neuronal injury and behavioral deficits, which were associated with an increase in microglia/macrophage infiltration in the peri-infarct region (Degos et al. 2013).

Inflammation after stroke can be beneficial. However, excessive inflammation during the acute phase can incur further damage (Hayakawa et al. 2010); conversely, reducing the inflammation during the acute phase of ischemic stroke decreases brain injury and improves functional outcome (Hayakawa et al. 2010). In addition, microglia and macrophages mobilize to the injury site following stroke (Schroeter et al. 1994), and can polarize into type I (pro-inflammatory, M1) and type II (anti-inflammatory, M2) (Kigerl et al. 2009; Durafourt et al. 2012; Hu et al. 2012). Reduction of M1 and...
increase of M2 macrophages may reduce neuronal injury and improve functional recovery.

Oxidative stress has been implicated in the pathogenesis of brain injuries during ischemic or hemorrhagic stroke (Klein and Ackerman 2003; Paravincini and Sobey 2003) through processes that involve nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Wang et al. 2013). Up-regulation of NADPH oxidase after brain injury triggers neuroinflammation and increases pro-inflammatory factors (Chen et al. 2011). NADPH oxidase is regulated by the inflammatory transcription factor, nuclear factor kappa b (NF-κb) (Anrather et al. 2006).

While cigarette smoking is considered a risk factor for ischemic stroke (Hawkins et al. 2002; Mazzone et al. 2010; Fujii et al. 2013; Raval et al. 2013; Naik et al. 2014), some animal studies have shown that nicotine has a beneficial effect on stroke recovery (Gonzalez et al. 2006; Yang et al. 2008). Alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) is ubiquitously expressed in the brain (Breese et al. 1997; Quik et al. 2009; Woodruff et al. 2011). In a rat subarachnoid hemorrhage model (Duris et al. 2011) and in a mouse intracerebral hemorrhage model (Krafft et al. 2012), activation of α-7 nAchR reduced brain injury. Potentiating α-7 nAchR using type-II positive allosteric modulator also reduces brain injury and improves neurological function after transient focal cerebral ischemia in rats (Sun et al. 2013). More importantly, α-7 nAchR expressed on the surface of macrophages is a pivotal regulator of NF-κb activity (Wang et al. 2003; Tracey 2009). Treatment of bone marrow-derived macrophages with an α-7 nAchR-specific agonist, PHA 568487 (PHA), prevented NF-κb activation in the cells (Terrando et al. 2011). Terrando et al. (2011) showed that PHA treatment reduces mouse cognitive decline caused by aseptic bone fracture by promoting inflammation resolution.

Previous studies attribute the neuroprotection of α-7 nAchR to its pro-survival effect (Duris et al. 2011; Krafft et al. 2012). In this study, using mice with stroke and tibia fracture, we tested the hypothesis that inhibition of neuroinflammation and oxidative stress are also underlying mechanisms of α-7 nAchR neuroprotection.

Methods

Animals

Animal experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco, and conformed to National Institutes of Health guidelines. Mice were fed standard rodent food and water ad libitum, and were housed (five per cage) in sawdust-lined cages in an air-conditioned environment with 12-h light/dark cycles.

C57BL/6j male mice (10–12 weeks old; Jackson Laboratory, Bar Harbor, ME, USA) were randomly assigned to each treatment group. Figure 1 shows the experimental design. Researchers, blinded to the group assignment, performed neurobehavioral tests, infarct volume assessment, and cell counting.

Permanent middle cerebral artery occlusion procedure

Mice were anesthetized with 2% isoflurane inhalation. A 1-cm skin lesion from the left orbit to the ear was made, followed by a 2 mm2 craniotomy under aseptic surgical conditions. The middle cerebral artery (MCA) was then permanently occluded (pMCAO) using electrical coagulation just proximal to the pyriform branch (Degos et al. 2013). The rectal temperature was maintained at 37 ± 0.5°C using a thermal blanket during surgery. A laser Doppler flow-meter (Vasamedics, Little Canada, MN, USA) was used to monitor the surface cerebral blood flow to ensure the success of MCA occlusion. Mice with surface cerebral blood flow in the ischemic core > 15% of the baseline, or had massive bleeding because of the artery injuries, were excluded from experiments. In this study, seven mice were killed as a result of massive arterial bleeding during the pMCAO procedure.

Fig. 1 Experimental design. (a) Time course for permanent middle cerebral artery occlusion (pMCAO) control. (b) Time course for the pMCAO + tibia fracture group. All mice underwent behavioral training 4 days before pMCAO. Baseline behavior performance was documented 1 day before pMCAO (D-1) and behavioral tests were performed 3 days (D3) after pMCAO. Tibial fracture was conducted 1 day (D1) after pMCAO. Drugs were injected i.p. 1 (first injection) and 2 days (second injection) after pMCAO. Brain samples were collected after the behavior tests 3 days after pMCAO.
procedure, and were replaced with additional mice housed in the same cages. Two doses of buprenorphine (0.1 mg/kg of body weight) were injected intraperitoneally at the beginning of the surgery and 4 h after. Mice were allowed to recover spontaneously under warm conditions.

**Tibia fracture procedure**

One day after the pMCAO procedure, animals were anesthetized with 2% isoflurane inhalation. Under aseptic surgical conditions, animals received an open tibia fracture on the right hind limb with an intramedullary fixation, as previously described (Cibelli et al. 2010). Animals were allowed to recover spontaneously from anesthesia under warm conditions. Rectal temperature was maintained at 37 ± 0.5°C using a thermal blanket throughout the surgical procedure. Two doses of buprenorphine (0.1 mg/kg of body weight) were injected intraperitoneally at the beginning of the surgery and 4 h after. The tibia fracture surgery did not cause any mortality.

**Chemical reagents**

PHA (Tocris Bioscience, Bristol, UK), a selective agonist of α-7 nAchR, and methyllycaconitine (MLA; Sigma, St Louis, MO, USA), an antagonist of α-7 nAchR, were diluted in 0.9% saline prior to use and injected at the time indicated in Fig. 1. Using pMCAO mice, we performed a dose–response study in which PHA (0.4 and 0.8 mg/kg) or MLA (4 and 6 mg/kg) were injected into the mice (i) once on day 1, or (ii) twice on days 1 and 2, after pMCAO. The testing doses were selected based on previous studies (Duris et al. 2011; Terrando et al. 2011). We found that injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests. Therefore, 0.8 mg/kg for PHA and 6 mg/kg for MLA were used in this study.

**Behavioral tests**

Adhesive removal test was performed to assess potential somatosensory neglect (Bouet et al. 2007). Briefly, a piece of adhesive tape (0.3 × 0.3 cm) was placed on one of the forepaws. The time it took for the mouse to remove the tape was recorded. The maximum testing time was 120 s. Mice were trained twice daily for 4 days before pMCAO to obtain an optimal level of performance. The adhesive removal times were recorded after two practice trials 1 day before pMCAO (D-1), and 3 days after (D3). Since the infarct in our model was on the left side of the brain, the adhesive removal times from the right paw were more relevant and are thus reported here.

Corner test was performed to detect sensorimotor and postural asymmetries after ischemic stroke (Zhang et al. 2007). Briefly, each mouse was placed at the corner of the box and the time it took for the mouse to move from the starting point to the opposite corner was recorded. The mice were scored as ‘positive’ if they moved to the opposite corner within 5 s. The maximum testing time was 50 s. A region of interest (ROI) was set to measure the number of sessions in which the mice entered the ROI within 5 s. The data are presented as mean ± SD. Gaussian distribution was tested with d’Agostino and Pearson omnibus normality test. Equality of variances was tested with the F-test. For comparisons of more than two groups, means were compared using one-way ANOVA followed by t-tests with a Bonferroni-corrected alpha level.

Cytokine level quantification

Brain samples were collected after being perfused with saline to prevent blood contamination. The cortex that contained the infarct and peri-infarct regions, from bregma 1.7 mm to −2.1 mm (about 8 mm3), was harvested under a dissection microscope and placed in RNAlater™ solution (Qiagen, Valencia, CA, USA). RNA was then extracted using Trizol Reagent (Qiagen), and reverse-transcribed using High-Capacity RNA to cDNA kit (Applied Biosystems, Carlsbad, CA, USA). TaqMan Fast Advanced Master Mix and gene-specific primers and probes from Applied Biosystems, including glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Mm99999915_g1), CD11b (Mm00440502_m1), CD206 (Mm00485148_m1), SOD1 (Mm01344233_g1), GPX1 (Mm00656767_g1), gp91phox (Mm01287743_m1), and p22phox (Mm00514478_m1), were used. Samples were run in triplicate. Specific gene expression was normalized to GAPDH and calculated using the comparative threshold cycle (ΔCT). Results were presented as fold-changes relative to the mean value of saline-treated pMCAO + tibia fracture mice.

Histological analysis

Three sections (200 μm apart) from each brain (selected from the same sets of serial sections used for infarct volume analysis) were used for each immunostaining as indicated below. Sections were incubated at 4°C overnight with the following primary antibodies: CD68 to detect active microglia/macrophages, 1 : 50; AbD Serotec, Raleigh, NC, USA), NeuN to label neuron, 1 : 500; Millipore, Bedford, MA, USA), Iba-1 (to label total microglia/macrophages, 1 : 200; Wako, Richmond, VA, USA), CD11b (to identify M1 cells, 1 : 200; AbD Serotec), CD206 (to identify M2 cells, 1 : 100; R&D, Minneapolis, MN, USA), and NF-κb (to measure the activity of NF-κb inflammatory pathway, 1 : 100; Cell Signaling, Danvers, MA, USA). After washing with phosphate-buffered saline, sections were then incubated with secondary antibodies: Alexa-594 or Alexa-488 IgG (1 : 500; Invitrogen, Carlsbad, CA, USA). Negative controls were performed by omitting the primary or the secondary antibodies during the staining procedure.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay was performed using ApopTag (Millipore). Positively stained cells were counted using Image J by three researchers who were blinded to the research groups.

Statistical analysis

Data are presented as mean ± SD. Gaussian distribution was tested with d’Agostino and Pearson omnibus normality test. Equality of variances was tested with the F-test. For comparisons of more than two groups, means were compared using one-way ANOVA followed by t-tests with a Bonferroni-corrected alpha level.
Results

α-7 nAChR agonist treatment reduced behavioral deficits

Mice subjected to pMCAO alone had impaired ability to remove the adhesive from their right paw ($p < 0.001$; saline-treated groups in Fig. 2a) and made more left turns on day 3 after pMCAO compared to baseline ($p < 0.001$; saline-treated groups in Fig. 2b). Tibia fracture alone did not affect the behavioral tests we used in the current study (Degos et al. 2013). Mice with pMCAO + tibia fracture took longer to remove the adhesive from the right paws ($p < 0.001$; saline-treated groups in Fig. 2a), and made more left turns ($p = 0.013$; Fig. 2b) than pMCAO mice on day 3 after pMCAO. These data are consistent with our previous report that tibia fracture 1 day after pMCAO exacerbates behavior deficit (Degos et al. 2013).

PHA treatment improved behavior performance in both pMCAO and pMCAO + tibia fracture groups. Compared to the saline group, PHA-treated pMCAO and pMCAO + tibia fracture mice took less time to remove the adhesive from the right paw (Fig. 2a), and made fewer left turns in the corner test (Fig. 2b). However, pMCAO + tibia fracture mice still took a longer time than pMCAO mice to remove adhesive from their right paws after PHA treatment ($p < 0.001$), again indicating that tibia fracture enhanced behavior dysfunction of mice with ischemic stroke injury.

MLA treatment increased adhesive removal time (right paw) in pMCAO and pMCAO + tibia mice (Fig. 2a), and left turns in the corner test (Fig. 2b).

α-7 nAChR agonist treatment reduced infarct volume and neuronal death

Tibia fracture, 1 day after pMCAO significantly increased the infarct volume ($p = 0.005$; saline-treated groups in Fig. 3b) and TUNEL positive neurons in the peri-infarct region ($p = 0.015$; saline-treated groups in Fig. 3e). These data are consistent with our previous finding that tibia fracture increases the neuronal damage of ischemic stroke (Degos et al. 2013). PHA reduced infarct volume (Fig. 3a and b) and TUNEL positive neurons in the peri-infarct regions (Fig. 3c–e) of pMCAO and pMCAO + tibia fracture mice. MLA increased infarct volume (Fig. 3a and b) and TUNEL positive neurons (Fig. 3c–e).

α-7 nAChR agonist treatment decreased microglia/macrophages

Compared to pMCAO mice, pMCAO + tibia fracture mice had more CD68$^+$ in the peri-infarct regions ($p = 0.02$; saline-treated groups in Fig. 4c), which indicated that tibia fracture enhanced neuroinflammation during the acute stage of stroke. PHA reduced the number of CD68$^+$ cells in the peri-infarct region of pMCAO ($p < 0.001$) and pMCAO + tibia fracture ($p = 0.017$) mice (Fig. 4). However, pMCAO + tibia fracture mice still had more CD68$^+$ cells than pMCAO after PHA treatment ($p = 0.03$), suggesting that the neuroinflammation in pMCAO + tibia fracture mice was more severe. MLA...
increased CD68+ cells in both pMCAO and pMCAO + tibia fracture mice (Fig. 4).

**α-7 nAChR agonist treatment reduced M1 microglia/macrophages**

The polarized microglia/macrophages are commonly distinguished by their expression of signature genes for surface markers and cytokines/chemokines (Hu et al. 2012). Using real-time PCR, we measured M1 (iNOS and CD11b) and M2 (CD206 and IL-10) marker gene expression in the infarct and peri-infarct regions. Results are presented as fold-changes relative to the mean value of saline-treated pMCAO + tibia fracture mice. pMCAO + tibia fracture mice expressed higher M1 markers than pMCAO mice: iNOS and CD11b (saline-treated groups in Fig. 5a and b). Tibia fracture did not change M2 marker, CD206, and IL-10 expression (Fig. 5c and d).

---

PHA reduced the expression of iNOS and CD11b (Fig. 5a and b), and increased CD206 and IL-10 (Fig. 5c and d). MLA increased the expression of iNOS and CD11b (Fig. 5a and b), and had no effect on the expression of CD206 and IL-10 (Fig. 5c and d). The expression of iNOS and CD11b was still higher in the pMCAO + tibia group compared with pMCAO-only group after PHA treatment, suggesting that with the dose we used, PHA did not completely inhibit inflammation induced by tibia fracture.

It is known that some of the M1 and M2 signature genes are expressed not only in microglia/macrophages but also in other cells in the brain. The results of real-time PCR, therefore, reflect the changes of these genes in brain tissues of mixed cell types. To evaluate whether the changes of gene expression had any indication of microglia/macrophages polarization after pMCAO or pMCAO + tibia fracture, representative M1 (CD11b)-associated or M2 (CD206)-associated marker proteins were analyzed using double immunofluorescent staining with the microglia/macrophage marker Iba1 on the peri-infarct region (Fig. 6). Consistent with the real-time PCR results, tibia fracture significantly increased M1 microglia/macrophages of pMCAO mice (saline-treated group in Fig. 6b), but had no influence on the number of M2 microglia/macrophages (saline-treated group in Fig. 6d).

Compared to saline, PHA reduced M1 and MLA increased M1 microglia/macrophages (Fig. 6a and b). PHA also increased M2 cells (Fig. 6c and d), whereas MLA did not change the number of M2 cells. The M1/M2 ratio decreased after PHA treatment and increased after MLA treatment (Fig. 6e).

Because it is difficult to identify the infarct border on the surface of the brain, we collected tissue from a slightly larger area than that used in the histological analysis in order to cover the variations of infarct size and location. Since majority of CD68+ cells were located right outside the infarct border (Fig. 4b) and few were detected in the infarct region, and although the tissues in the infarct core were included in the PCR analysis, we believed that both PCR and histological analyses would measure the same M1/M2 response.

**α-7 nAchR agonist treatment increased anti-oxidant gene expression and reduced NADPH oxidase and NF-κb phosphorylation**

To test whether α-7 nAchR agonist reduces oxidative stress, we analyzed the expression of anti-oxidant genes, superoxide dismutase 1 (SOD1), and glutathione peroxidase 1 (GPX1), and the expression of the two subunits of pro-oxidative stress protein NADPH oxidase (gp91phox and p22phox), using quantitative RT-PCR. NF-κb activity was analyzed by quantifying phospho-NF-κb p65 positive microglia/macrophages in the peri-infarct region of pMCAO and pMCAO + tibia fracture mice, using phospho-NF-κb p65 and Iba1 antibody-stained sections. Tibia fracture reduced the expression of SOD1 and GPX1, and increased the expression of gp91phox and p22phox (Fig. 7a–d). PHA increased the expression of SOD1 and GPX1, and decreased the expression of gp91phox and p22phox (Fig. 7a–d) and p22phox ($p = 0.006$, Fig. 7d).


**Discussion**

In this study, we examined the effects of PHA, the α-7 nAchR agonist, on neuroinflammation, and neuronal injury in mice with contemporaneous ischemic stroke and bone fracture. We found that administration of PHA 1 and 2 days after pMCAO reduced neuronal injury and improved functional recovery. Interestingly, PHA increased anti-oxidant gene expression and reduced microglia/macrophage infiltration, M1/M2 microglia/macrophage ratio, pro-oxidative NADPH oxidase, and NF-kb activity (Table 1). These data suggest that reduction of neuroinflammation and oxidative stress might be one of the underlying mechanisms of α-7 nAchR neuroprotective effect.

We previously demonstrated that tibia fracture 1 day after ischemic stroke exacerbates neuroinflammation and injury. Blocking high-mobility-group box chromosomal protein-1 using an high-mobility-group box chromosomal protein-1 antibody or depletion of macrophage with clodrolip attenuated the effects of bone fracture on stroke recovery (Degos et al. 2013). In this study, we found that tibia fracture increased the ratio of M1/M2 microglia/macrophages, NADPH oxidase and NF-kb activity, and reduced anti-oxidant gene expression. We also showed that the α-7 nAchR agonist, PHA, attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture.

In addition, we demonstrated that the nAchR antagonist, MLA, had opposite effects to those of the agonist, PHA. MLA-treated mice had significantly more microglia/macrophages in the peri-infarct region, larger infarct size, more apoptotic neurons, and poorer behavioral recovery compared to either saline-treated controls or PHA-treated group. It has been reported that MLA impairs normal mouse behavior and increases neuroinflammation (Chilton et al. 2004). Our findings differ from the hemorrhagic stroke model in which MLA did not exacerbate behavioral dysfunction or increase brain edema (Krafft et al. 2012). One of the reasons is that the neuroinflammation in the hemorrhagic stroke model is more severe than in our pMCAO model, and a greater dose of MLA may be needed to precipitate its adverse effect.

Microglia/macrophages can be classified into two extreme phenotypes: M1 or M2. M1 mediates host defense and is pro-inflammatory, while M2 plays anti-inflammatory roles (Murray and Wynn 2011). Increased M1 microglia/macrophages could escalate tissue damage after stroke (Hu et al. 2012). We demonstrated that activation of α-7 nAchR by PHA decreased the M1 and M2 microglia/macrophage ratio. Because M2 macrophages play an anti-inflammatory role and have been shown to promote axon regeneration in culture (Kigerl et al. 2009), our finding suggests that the decreased M1/M2 ratio contributed to reduced ischemic injury in our model.

A previous study using a transient MCAO mouse model showed that M2 macrophages at the early stage of stroke were eventually replaced by M1 cells (Hu et al. 2012); the macrophage outcome in our stroke and bone fracture model is unknown. However, our results showed that tibia fracture increased M1 in the peri-infarct region without affecting M2 microglia/macrophages, suggesting that bone fracture increases neuroinflammation by promoting M1 macrophage infiltration or polarization. This needs verification through experiments.
the use of transgenic mice expressing marker genes in different subtypes of microglia/macrophage, such as IL-12/23p40 (for M1) (Reinhardt et al. 2006), YARG [mice with an enhanced yellow fluorescent protein (eYFP) fusion protein, downstream of the endogenous stop codon of the arginase (Arg1) gene] (for M2) (Reese et al. 2007), and Ccr2-RFP/Cx3cr1GFP+ (for distinguishing microglia and macrophages) (Saederup et al. 2010).

Fig. 6 Alpha-7 nicotinic acetylcholine receptor (α7 nAchR) agonist treatment reduced M1/M2 ratios. (a) Representative images of CD11b and Iba1 antibody-stained sections of permanent middle cerebral artery occlusion (pMCAO) + tibia fracture mice. Nuclei were counter-stained with DAPI. Scale bars = 50 μm. (b) Quantification of M1 macrophages (CD11b+/Iba1+). *p < 0.001, versus saline-treated pMCAO only mice; #p = 0.014 and $p = 0.011 versus saline-treated pMCAO + tibia fracture mice. (c) Representative images of CD206 and Iba1 antibody-stained sections of pMCAO + tibia fracture mice. Nuclei were counter-stained with DAPI. Scale bar = 50 μm. (d) Quantification of M2 macrophages (CD206+/Iba1+). *p < 0.001, versus saline-treated pMCAO only mice; $p = 0.001 versus saline-treated pMCAO + tibia fracture mice. (e) M1 to M2 ratios. *p = 0.017, #p = 0.002, and $p = 0.001 versus saline-treated pMCAO mice; $p = 0.003 and #p = 0.017 versus saline-treated pMCAO + tibia fracture mice. S: pMCAO; T: tibia fracture.
We showed that PHA inhibits NF-kB phosphorylation, consistent with our previous finding that PHA treatment prevents TNFα (tumor necrosis factor alpha) induced NF-kB activation in the hippocampi of tibia fracture mice (Terrando et al. 2011). In a hemorrhagic stroke model, Krafft et al. (2012) demonstrated that PHA confers neuroprotection by reducing the expression of pro-apoptotic GSK-3β (glycogen synthase kinase 3 beta) and activation of PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase)-Akt pathway. PI3K Akt has also been shown to inhibit NF-kB signaling (Guha and Mackman 2002). Therefore, decreased phospho-NF-kB p65 after PHA in our model may act through the PI3K-Akt pathway as well.

α-7 nAChR modulates vascular tones of cerebral arteries (Si and Lee 2002), but because it is difficult to monitor α-7 nAChR agonist/antagonist in awakened mice, we were not able to measure its effect on cerebral blood flow. Anesthesia could influence hemodynamic measurement and additional surgery procedure could cause additional inflammatory response, which would have complicated our analysis.

In summary, using a mouse model of pMCAO and tibia fracture, we showed that α-7 nAChR agonist treatment decreases peri-infarct microglia/macrophage infiltration, shifts microglia/macrophage polarization from M1 to M2, and down-regulates NF-kB activity and oxidative gene expression, which are associated with reduction in neuronal.
Table 1 Summary of the effects of PHA and MLA

<table>
<thead>
<tr>
<th></th>
<th>PHA</th>
<th>MLA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S</td>
<td>S + T</td>
</tr>
<tr>
<td>Behavior tests</td>
<td>Improved</td>
<td>Improved</td>
</tr>
<tr>
<td>Infarct size</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>Apoptotic neurons</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>CD68* cells</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>M1 gene</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>M2 gene</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>M1 cells</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>M2 cells</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>M1/M2 ratio</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>Anti-oxidant gene</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>NADPH oxidase</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>NF-κb</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
</tbody>
</table>

S, pmCAO only; S + T, pmCAO + tibia fracture.

injury and behavior deficits. Our data indicate that in addition to a previously recognized pro-survival effect, α-7 nAChR agonist also acts through down-regulation of neuroinflammation and oxidative stress. Although our study could not determine if PHA’s beneficial effects are secondary to the inhibition of stroke or bone-induced neuroinflammation, the fact that PHA reduces the overall neuronal injury and functional deficits in treated mice indicate that activation of α-7 nAChR could be a therapeutic opportunity for improving the outcomes of patients with stroke and bone fracture.

Acknowledgments and conflict of interest disclosure

This study was supported by NIH grants P01 NS044155, R21 NS070153, R01 NS027713, and R01 GM104194. We would also like to acknowledge the support provided by the Fondation des Gueules Cassées, Paris, France. The authors thank Voltaire Gungab for manuscript preparation, and members of the UCSF Brain Arteriovenous Malformation (BAVM) Project (http://avm.ucsf.edu) for their support. The authors have no conflicts of interest to declare.

All experiments were conducted in compliance with the ARRIVE guidelines.

References


